Bausch Health shares rise as Q2 earnings soar past estimates

Published 30/07/2025, 23:26
Bausch Health shares rise as Q2 earnings soar past estimates

Investing.com -- Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) reported second-quarter earnings that significantly exceeded analyst expectations, driving shares up 2.8% as investors responded positively to the company’s strong performance and upbeat outlook.

The pharmaceutical company posted adjusted earnings per share of $0.40 for the second quarter, dramatically surpassing the analyst consensus of $0.04. Revenue reached $2.53 billion, beating estimates of $2.48 billion and representing a 5% increase compared to $2.40 billion in the same quarter last year.

"In the second quarter, we achieved our ninth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb," said Thomas J. Appio, Chief Executive Officer of Bausch Health. "This consistent performance highlights our operational excellence and the strength of our diverse portfolio across therapeutic areas and geographies."

The company’s Salix segment was a standout performer with 12% YoY growth to $627 million, driven primarily by its Xifaxan product, which saw 10% revenue growth. The Solta Medical (TASE:BLWV) segment also delivered impressive results with a 25% increase to $128 million.

Bausch Health raised its full-year 2025 guidance, now projecting revenue between $10 billion and $10.25 billion, compared to the analyst consensus of $10.037 billion. The company also increased its Adjusted EBITDA forecast to between $3.485 billion and $3.635 billion, representing growth of 3% to 7% over the prior year.

The company generated $289 million in cash from operating activities during the quarter, though this represented a 24% decrease from the $380 million generated in the second quarter of 2024.

Bausch Health continues to focus on strengthening its balance sheet and advancing its R&D pipeline, with several products in late-stage development including RED-C for hepatic encephalopathy, with Phase 3 results anticipated by early 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.